28 February 2026
Merck's KEYTRUDA and WELIREG Combo Reduces RCC Recurrence Risk by 28%
Phase 3 trial shows KEYTRUDA and WELIREG improve disease-free survival in RCC. FDA accepts priority review for adjuvant treatment. Safety profile consistent with previous studies.